ChemT Biotechnology has successfully raised $5 million in funding to enhance its AI-driven biomanufacturing platform, with the seed round led by Wavemaker Ventures and participation from various notable investors.
The funding consists of $1 million from angel investors and $4 million from a seed round aimed at expanding ChemT's AI capabilities and experimental infrastructure. The company's innovative approach seeks to streamline the manufacturing of biologics, which often face challenges such as lengthy development timelines, high costs, and inconsistent yields.
Central to ChemT's strategy is its CelMo™ platform, which utilizes AI to model cellular responses to various manufacturing conditions. This technology has already shown promising results, including a 50% increase in antibody production and a 40% reduction in timelines for CHO cells, commonly used in therapeutic protein manufacturing. Additionally, ChemT's Chemplify™ product has demonstrated significant advancements in T-cell manufacturing, crucial for cancer therapies.
The funding will support the scaling of ChemT's partnerships with over 40 pharmaceutical and biotech companies, as well as the expansion of the CelMo™ platform to include other cell types. The company's mission is to revolutionize biomanufacturing by integrating intelligence into the process, thus facilitating faster and more efficient production of advanced medicines.
This investment underscores the growing recognition of the need for innovative solutions in biomanufacturing, particularly as the industry grapples with structural inefficiencies. By leveraging AI to gain a deeper understanding of cellular behavior, ChemT aims to transform the landscape of drug manufacturing, making it more scalable and cost-effective.